trending Market Intelligence /marketintelligence/en/news-insights/trending/ZXqg-IRk1UU1eB94YdbIWw2 content esgSubNav
In This List

Lexicon's Zynquista helps treat type 2 diabetes in late-stage study

Blog

Insight Weekly: Banks brace for recession; Europe PE deal values soar; US solar imports rebound

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook


Lexicon's Zynquista helps treat type 2 diabetes in late-stage study

Lexicon Pharmaceuticals Inc.'s diabetes drug Zynquista beat placebo and matched Eli Lilly and Co.'s Jardiance in reducing blood sugar levels of certain patients with type 2 diabetes in a late-stage study.

The Sota-Empa multicenter study compared the effectiveness of Zynquista, placebo and empagliflozin, sold by Lilly and Boehringer Ingelheim GmbH under brand name Jardiance, on 700 patients over a 26 week period.

Patients in the study had inadequate sugar metabolism from type 2 diabetes, despite using a class of oral drugs known as Dipeptidyl peptidase-4 inhibitors, which help preserve a group of hormones that decrease glucose levels in the blood.

The company expects top-line results from its remaining late-stage studies of Zynquista in early 2020, Lexicon's executive vice president and chief medical officer, Pablo Lapuerta, said in a statement.

Zynquista, or sotagliflozin, was approved by the European Commission in April as an add-on therapy for adults with type 1 diabetes. In contrast, the U.S Food and Drug Administration rejected it for the same treatment and denied the Woodlands, Texas-based company's appeal over the rejection.